Actividad Investigadora
Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors
Fecha de publicación:
Fecha Ahead of Print:
Autores de IDIVAL
Autores ajenos al IDIVAL
- Calleja JL
- Hernández-Conde M
- Vera MI
- Frias Y
Unidades
Abstract
BACKGROUND & AIMS: There is conflicting evidence regarding the prevalence of and risk factors for metabolic-associated fatty liver disease (MAFLD) in patients with inflammatory bowel disease (IBD). We aimed to determine MAFLD prevalence and risk factors in IBD patients.METHODS: Cross-sectional, case-control study included all consecutive IBD patients treated at 2 different university hospitals. Controls were subjects randomly selected from the general population and matched by age, sex, type 2 diabetes status, and body mass index in a 1:2 ratio. MAFLD was confirmed by controlled attenuation parameter. Liver biopsies were collected when MAFLD with significant liver fibrosis was suspected. In addition, age-and fibrosis stage-paired non-IBD patients with biopsy-proven MAFLD served as a secondary control group.RESULTS: Eight hundred thirty-one IBD patients and 1718 controls were included. The prevalence of MAFLD and advanced liver fibrosis (transient elastography double dagger 9.7 kPa) was 42.00% and 9.50%, respectively, in IBD patients and 32.77% and 2.31%, respectively, in the general population (P < .001). A diagnosis of IBD was an independent predictor of MAFLD (adjusted odds ratio, 1.99; P < .001) and an independent risk factor for advanced liver fibrosis (adjusted odds ratio, 5.55; P < .001). Liver biopsies were obtained from 40 IBD patients; MAFLD was confirmed in all cases, and fibrosis of any degree was confirmed in 25 of 40 cases (62.5%). Body mass index and type 2 diabetes prevalence were significantly lower in IBD-MAFLD patients than in severity-paired patients with biopsy-proven MAFLD. CONCLUSIONS: MAFLD and liver fibrosis are particularly prevalent in IBD patients, regardless of the influence of classic metabolic risk factors.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1542-7714, 1542-7714
- Tipo:
- Article
- Páginas:
- 406-4147
- PubMed:
- 35124272
- Enlace a otro recurso:
- www.sciencedirect.com
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 60
Documentos
- No hay documentos
Filiaciones
Keywords
- MAFLD; Inflammatory Bowel Disease; Liver Fibrosis; Metabolic Syndrome
Campos de Estudio
Cita
Rodriguez JC, Calleja JL, Iruzubieta P, Hernández M, Rivas C, Vera MI, Garcia MJ, Pascual M, Castro B, García A, García E, Olmo SC, Cagigal ML, Lopez L, Fernández T, Rasines L, Fortea JI, Vaque JP, Frias Y, Rivero M, Arias MT, Crespo J. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors. Clin Gastroenterol Hepatol. 2023. 21. (2):p. 406-4147. IF:12,600. (1).
